Issues in the systematic review of drugs for rare diseases: A case study of Eculizumab for AHUS (2012)
Atypical haemolytic uraemic syndrome (aHUS) is a rare disease affecting approximately 170 people in the UK. The outcome is often poor, with 53% of familial cases and 37% of sporadic cases resulting in end stage renal failure or death. A systematic review was undertaken to assess the efficacy and safety of eculizumab for aHUS. We report key outcomes and highlight issues of applying standard systematic review methods where the evidence base is not well developed.
EthicsThere is no personal data or any that requires ethical approval
PolicyThe data complies with the institution and funders' policies on access and sharing
Sharing and access restrictionsThe data can be shared openly
- The file formats are open or commonly used
Methodology, headings and units
- Headings and units are explained in the files